Paradoxical Bronchoconstriction with Short-Acting Beta Agonist.

Area of Science:

• Pulmonology
• Allergy and Immunology
• Pharmacology

Background:

• Asthma management commonly involves short-acting beta-2 agonists (SABAs) for symptom relief.
• SABAs are intended to relax airway smooth muscle, but can paradoxically cause bronchospasm.
• This adverse event is an under-recognized complication of SABA inhaler formulations.

Observation:

• A 25-year-old male with moderate asthma experienced acute shortness of breath after using albuterol inhalers.
• Pulmonary function tests (PFTs) with both levalbuterol and albuterol demonstrated decreased FEV1 and FVC.
• Nebulized treatments with albuterol and ipratropium bromide showed improvement in respiratory function.

Findings:

• The patient exhibited paradoxical bronchoconstriction, a rare adverse reaction to SABA therapy.
• Formulation excipients in SABA inhalers may trigger airway hyperresponsiveness in patients with inflamed airways.
• Transitioning to an ipratropium rescue inhaler resolved the patient's exacerbations.

Implications:

• Clinicians must recognize paradoxical bronchospasm as a potential adverse effect of common SABA inhalers.
• Consideration of alternative rescue inhalers, such as ipratropium, is crucial for affected patients.
• Patient counseling regarding this adverse event is essential for appropriate asthma management.